Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 27;12(3):e008585. doi: 10.1136/jitc-2023-008585

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Changes in tumor size and immune cells during tumorigenesis and treatment in cell line-derived xenograft (CDX)-humanized mouse model. (A) Cellular viability against osimertinib using MTT assay in HCC827/OR and PC-9/OR cell lines. (B) Quantitative measurement of human-specific immune cells in preclinical reenactment humanized mouse model in this study. (C) Tumor growth tracking using an in vivo imaging system. (D) Changes in tumor size according to treatment. (E) Extracted tumor after treatment. (F) Changes in pan-NK marker (CD45+/CD56+) in immune cells of CDX-humanized mice during tumorigenesis and treatment. (G) Immunohistochemistry analysis of tumor extracted from CDX-humanized mouse model according to treatment *p<0.05, **p<0.01, ***p<0.001. MTT; 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide.